Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash-to-Debt 0.38
NAS:AKRX's Cash-to-Debt is ranked lower than
73% of the 815 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.12 vs. NAS:AKRX: 0.38 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:AKRX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.35 Max: No Debt
Current: 0.38
Equity-to-Asset 0.43
NAS:AKRX's Equity-to-Asset is ranked lower than
77% of the 739 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.63 vs. NAS:AKRX: 0.43 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:AKRX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.1  Med: 0.54 Max: 0.95
Current: 0.43
0.1
0.95
Interest Coverage 7.72
NAS:AKRX's Interest Coverage is ranked lower than
76% of the 638 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 118.48 vs. NAS:AKRX: 7.72 )
Ranked among companies with meaningful Interest Coverage only.
NAS:AKRX' s Interest Coverage Range Over the Past 10 Years
Min: 1.71  Med: 7.4 Max: No Debt
Current: 7.72
Piotroski F-Score: 7
Altman Z-Score: 3.80
Beneish M-Score: -2.39
WACC vs ROIC
10.61%
15.16%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating Margin % 28.57
NAS:AKRX's Operating Margin % is ranked higher than
92% of the 767 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.94 vs. NAS:AKRX: 28.57 )
Ranked among companies with meaningful Operating Margin % only.
NAS:AKRX' s Operating Margin % Range Over the Past 10 Years
Min: -37.46  Med: 17.96 Max: 29.91
Current: 28.57
-37.46
29.91
Net Margin % 16.64
NAS:AKRX's Net Margin % is ranked higher than
80% of the 769 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.26 vs. NAS:AKRX: 16.64 )
Ranked among companies with meaningful Net Margin % only.
NAS:AKRX' s Net Margin % Range Over the Past 10 Years
Min: -36.24  Med: 14.56 Max: 31.41
Current: 16.64
-36.24
31.41
ROE % 23.25
NAS:AKRX's ROE % is ranked higher than
86% of the 792 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.84 vs. NAS:AKRX: 23.25 )
Ranked among companies with meaningful ROE % only.
NAS:AKRX' s ROE % Range Over the Past 10 Years
Min: -50.57  Med: 21.2 Max: 35.12
Current: 23.25
-50.57
35.12
ROA % 9.42
NAS:AKRX's ROA % is ranked higher than
76% of the 821 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.58 vs. NAS:AKRX: 9.42 )
Ranked among companies with meaningful ROA % only.
NAS:AKRX' s ROA % Range Over the Past 10 Years
Min: -33.5  Med: 8.42 Max: 24.27
Current: 9.42
-33.5
24.27
ROC (Joel Greenblatt) % 63.14
NAS:AKRX's ROC (Joel Greenblatt) % is ranked higher than
88% of the 807 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.07 vs. NAS:AKRX: 63.14 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:AKRX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -48.35  Med: 56.63 Max: 77.64
Current: 63.14
-48.35
77.64
3-Year Revenue Growth Rate 47.10
NAS:AKRX's 3-Year Revenue Growth Rate is ranked higher than
96% of the 640 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.20 vs. NAS:AKRX: 47.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:AKRX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -37.1  Med: 10.6 Max: 56.6
Current: 47.1
-37.1
56.6
3-Year EBITDA Growth Rate 54.10
NAS:AKRX's 3-Year EBITDA Growth Rate is ranked higher than
92% of the 606 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.20 vs. NAS:AKRX: 54.10 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
NAS:AKRX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -2.8 Max: 149.9
Current: 54.1
0
149.9
3-Year EPS without NRI Growth Rate 47.30
NAS:AKRX's 3-Year EPS without NRI Growth Rate is ranked higher than
89% of the 580 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.90 vs. NAS:AKRX: 47.30 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:AKRX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -50.4  Med: 18.6 Max: 93.1
Current: 47.3
-50.4
93.1
GuruFocus has detected 4 Warning Signs with Akorn Inc $NAS:AKRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:AKRX's 30-Y Financials

Financials (Next Earnings Date: 2017-08-04 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NAS:OPK, OTCPK:STDAF, NYSE:MNK, NYSE:CTLT, NYSE:TARO, OTCPK:HKMPY, NYSE:PTHN, OTCPK:HYPMY, NAS:IRWD, NYSE:VRX, NAS:MDCO, NAS:ENDP, NAS:SUPN, OTCPK:EVTCY, NAS:RDUS, NAS:HZNP, NAS:PCRX, OTCPK:GZPHY, NYSE:RDY, NAS:PAHC » details
Traded in other countries:FDA.Germany,
Headquarter Location:USA
Akorn Inc is a generic pharmaceutical company that develops, manufactures and markets generic and branded prescription pharmaceuticals and branded as well as private-label over-the-counter consumer health products and animal health pharmaceuticals.

Akorn manufactures ophthalmology and dermatology products as well as injectables. In ophthalmology, the firm primarily sells generic and over-the-counter products but has a small branded portfolio that was purchased from Merck. The firm is primarily focused on the United States.

Top Ranked Articles about Akorn Inc

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Akorn, Inc. (AKRX)
Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of Akorn, Inc. - AKRX
Robert Olstein's Largest 1st-Quarter Buys Alphabet, Hormel, ExxonMobil on the list
Robert Olstein (Trades, Portfolio) is the chairman and chief investment officer of the Olstein Financial Alert Fund. During the first quarter the guru bought shares in the following stocks: Read more...
Lifshitz & Miller LLP Announces Investigation of AdvancePierre Foods Holdings, Inc., Akorn, Inc., AllianceMMA, Inc., Altisource Portfolio Solutions, DelTaco Restaurants, Inc., Express Scripts Holding Company, China Unicom (Hong Kong) Limited, and Global E
AKORN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akorn, Inc.
Harwood Feffer LLP Announces Investigation of Akorn, Inc.
AKORN (AKRX) ALERT: J&W Launches Investigation into the Sale of Akorn; Is $34 a Fair Price?
FPA Capital Buys 2 Beaten-Down Stocks, Energy in Fourth Quarter Fund buys stocks at low points
FPA Capital released its first portfolio update of 2017, disclosing purchase of two new positions and a raft of oil and gas stocks as it adhered to its guideline of selling equities that approach intrinsic value and buying those with a margin of safety and price discount to intrinsic value. Read more...
FPA Capital Invests in Akorn Company is expanding its operations
FPA Capital Fund (Trades, Portfolio) seeks long-term growth through the careful selection of common stocks and select fixed-income securities. During the first quarter it purchased 380,120 shares in Akorn Inc. (NASDAQ:AKRX) Read more...
Akorn Confirms Discussions with Fresenius Kabi

Ratios

vs
industry
vs
history
PE Ratio 22.83
AKRX's PE Ratio is ranked higher than
60% of the 561 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 26.96 vs. AKRX: 22.83 )
Ranked among companies with meaningful PE Ratio only.
AKRX' s PE Ratio Range Over the Past 10 Years
Min: 12.14  Med: 33.68 Max: 495
Current: 22.83
12.14
495
Forward PE Ratio 21.19
AKRX's Forward PE Ratio is ranked lower than
59% of the 68 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.46 vs. AKRX: 21.19 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 22.83
AKRX's PE Ratio without NRI is ranked higher than
61% of the 558 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 27.64 vs. AKRX: 22.83 )
Ranked among companies with meaningful PE Ratio without NRI only.
AKRX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 12.14  Med: 33.68 Max: 495
Current: 22.83
12.14
495
Price-to-Owner-Earnings 22.01
AKRX's Price-to-Owner-Earnings is ranked higher than
68% of the 304 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 33.00 vs. AKRX: 22.01 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
AKRX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 11.08  Med: 51.05 Max: 332.16
Current: 22.01
11.08
332.16
PB Ratio 4.79
AKRX's PB Ratio is ranked lower than
73% of the 761 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.88 vs. AKRX: 4.79 )
Ranked among companies with meaningful PB Ratio only.
AKRX' s PB Ratio Range Over the Past 10 Years
Min: 1.42  Med: 6.41 Max: 16.87
Current: 4.79
1.42
16.87
PS Ratio 3.81
AKRX's PS Ratio is ranked lower than
58% of the 743 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.96 vs. AKRX: 3.81 )
Ranked among companies with meaningful PS Ratio only.
AKRX' s PS Ratio Range Over the Past 10 Years
Min: 0.75  Med: 6.19 Max: 12.98
Current: 3.81
0.75
12.98
Price-to-Free-Cash-Flow 21.44
AKRX's Price-to-Free-Cash-Flow is ranked higher than
60% of the 209 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 25.35 vs. AKRX: 21.44 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
AKRX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 10.51  Med: 83.49 Max: 2950
Current: 21.44
10.51
2950
Price-to-Operating-Cash-Flow 14.66
AKRX's Price-to-Operating-Cash-Flow is ranked higher than
61% of the 281 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 19.13 vs. AKRX: 14.66 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
AKRX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 9.08  Med: 46.3 Max: 192.86
Current: 14.66
9.08
192.86
EV-to-EBIT 14.87
AKRX's EV-to-EBIT is ranked higher than
68% of the 563 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.48 vs. AKRX: 14.87 )
Ranked among companies with meaningful EV-to-EBIT only.
AKRX' s EV-to-EBIT Range Over the Past 10 Years
Min: -186.6  Med: 14.65 Max: 213.1
Current: 14.87
-186.6
213.1
EV-to-EBITDA 11.66
AKRX's EV-to-EBITDA is ranked higher than
71% of the 591 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 17.55 vs. AKRX: 11.66 )
Ranked among companies with meaningful EV-to-EBITDA only.
AKRX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -560.8  Med: 15.2 Max: 2955.7
Current: 11.66
-560.8
2955.7
PEG Ratio 0.46
AKRX's PEG Ratio is ranked higher than
91% of the 314 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.97 vs. AKRX: 0.46 )
Ranked among companies with meaningful PEG Ratio only.
AKRX' s PEG Ratio Range Over the Past 10 Years
Min: 0.06  Med: 0.41 Max: 0.65
Current: 0.46
0.06
0.65
Shiller PE Ratio 80.84
AKRX's Shiller PE Ratio is ranked lower than
78% of the 197 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 38.91 vs. AKRX: 80.84 )
Ranked among companies with meaningful Shiller PE Ratio only.
AKRX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 50.27  Med: 118.92 Max: 2690.5
Current: 80.84
50.27
2690.5
Current Ratio 4.21
AKRX's Current Ratio is ranked higher than
72% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.40 vs. AKRX: 4.21 )
Ranked among companies with meaningful Current Ratio only.
AKRX' s Current Ratio Range Over the Past 10 Years
Min: 0.21  Med: 2.42 Max: 17
Current: 4.21
0.21
17
Quick Ratio 3.22
AKRX's Quick Ratio is ranked higher than
70% of the 795 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.84 vs. AKRX: 3.22 )
Ranked among companies with meaningful Quick Ratio only.
AKRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.02  Med: 1.35 Max: 12.29
Current: 3.22
0.02
12.29
Days Inventory 149.73
AKRX's Days Inventory is ranked lower than
66% of the 713 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.36 vs. AKRX: 149.73 )
Ranked among companies with meaningful Days Inventory only.
AKRX' s Days Inventory Range Over the Past 10 Years
Min: 118.8  Med: 148.93 Max: 188.37
Current: 149.73
118.8
188.37
Days Sales Outstanding 77.41
AKRX's Days Sales Outstanding is ranked lower than
52% of the 651 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 74.70 vs. AKRX: 77.41 )
Ranked among companies with meaningful Days Sales Outstanding only.
AKRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 25.46  Med: 61.64 Max: 123.33
Current: 77.41
25.46
123.33
Days Payable 41.87
AKRX's Days Payable is ranked lower than
77% of the 597 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.86 vs. AKRX: 41.87 )
Ranked among companies with meaningful Days Payable only.
AKRX' s Days Payable Range Over the Past 10 Years
Min: 19.92  Med: 53.34 Max: 123.76
Current: 41.87
19.92
123.76

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.80
AKRX's 3-Year Average Share Buyback Ratio is ranked lower than
65% of the 477 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. AKRX: -8.80 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
AKRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -63.1  Med: -4.6 Max: 1.2
Current: -8.8
-63.1
1.2

Valuation & Return

vs
industry
vs
history
Price-to-Intrinsic-Value-Projected-FCF 2.10
AKRX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
55% of the 329 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.29 vs. AKRX: 2.10 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
AKRX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 1.51  Med: 9.66 Max: 749
Current: 2.1
1.51
749
Price-to-Median-PS-Value 0.62
AKRX's Price-to-Median-PS-Value is ranked higher than
88% of the 718 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.08 vs. AKRX: 0.62 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
AKRX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.04  Med: 0.28 Max: 1.96
Current: 0.62
0.04
1.96
Price-to-Peter-Lynch-Fair-Value 0.91
AKRX's Price-to-Peter-Lynch-Fair-Value is ranked higher than
75% of the 207 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.59 vs. AKRX: 0.91 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
AKRX' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 0.47  Med: 1.02 Max: 2.77
Current: 0.91
0.47
2.77
Earnings Yield (Greenblatt) % 6.71
AKRX's Earnings Yield (Greenblatt) % is ranked higher than
78% of the 820 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.97 vs. AKRX: 6.71 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AKRX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -19.6  Med: 2.6 Max: 11.2
Current: 6.71
-19.6
11.2
Forward Rate of Return (Yacktman) % 55.41
AKRX's Forward Rate of Return (Yacktman) % is ranked higher than
95% of the 381 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.46 vs. AKRX: 55.41 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
AKRX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -15.5  Med: -0.8 Max: 1017.5
Current: 55.41
-15.5
1017.5

More Statistics

Revenue (TTM) (Mil) $1,101.92
EPS (TTM) $ 1.47
Beta1.69
Short Percentage of Float7.66%
52-Week Range $17.61 - 35.40
Shares Outstanding (Mil)124.76

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 1,032 1,073 1,125
EPS ($) 1.60 1.73 1.80
EPS without NRI ($) 1.60 1.73 1.80
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AKRX

Headlines

Articles On GuruFocus.com
Credit Suisse Income Fund Announces Monthly Dividend Jun 27 2017 
GAMCO Analyst: Is VMware a Compelling Investment Idea in Data Infrastructure? Jun 26 2017 
Gabelli TV: 2017 American Water Works Annual Conference Recap Jun 26 2017 
Monthly Dividend Stocks to Pay Your Bills Jun 26 2017 
The Rubicon Project: Who Is Selling and Why It's Creating a Bargain Price Jun 26 2017 
Sports, Stocks and the Magic Quadrants Jun 26 2017 
Israel Englander More Than Doubles Stake in Carter's Jun 27 2017 
GMO Global Equity Insights - Whiplash: On Value, Growth and Ignoring the Fundamentals Jun 26 2017 
Dan Loeb's Third Point Letter on $3.5 Billion Nestle Purchase, Plans to Sells L'Oreal Jun 26 2017 
Canaries in the Coal Mine – What to Watch as Stocks Continue to Make New Highs Jun 26 2017 

More From Other Websites
SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Files Class Action Suit Against Akorn, Inc. Jun 22 2017
ETFs with exposure to Akorn, Inc. : June 19, 2017 Jun 19 2017
Top 3 Companies Owned by Valeant (VRX) Jun 19 2017
Akorn, Inc. :AKRX-US: Earnings Analysis: Q1, 2017 By the Numbers : June 16, 2017 Jun 16 2017
Shareholder Alert: Monteverde & Associates PC Announces An Investigation Of Akorn, Inc. - AKRX May 23 2017
Fresenius Tops Estimates, Raises Outlook May 03 2017
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces an Investigation of Akorn, Inc. -AKRX May 01 2017
How Trump’s First 100 Days Affected the Healthcare Industry May 01 2017
Fresenius Buys Akorn -- What Now? May 01 2017
Merger Buzz Drives Akorn to Top of Health Chart in April Apr 30 2017
INVESTOR ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Akorn, Inc. and... Apr 30 2017
Lifshitz & Miller LLP Announces Investigation of AdvancePierre Foods Holdings, Inc., Akorn, Inc.,... Apr 28 2017
SHAREHOLDER ALERT: Brower Piven Commences an Investigation into the Proposed Sale of Akorn, Inc. and... Apr 26 2017
Akorn, Inc. -- Moody's reviews Akorn's ratings for upgrade Apr 26 2017
Fresenius US Finance II, Inc. -- Moody's affirms Fresenius SE's Baa3 issuer rating, outlook stable Apr 26 2017
Why Mylan, Perrigo and Endo Won't Be Playing Spoiler in Akorn-Fresenius Tie Up Apr 25 2017
AKORN INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC... Apr 25 2017
[$$] Fresenius Makes Two Acquisitions to Boost Kabi Clinical Unit Apr 25 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}